Cost of Illness Diabetes Melitus Tipe 2 dan Komplikasinya pada Peserta Jaminan Kesehatan Nasional (JKN) di Rawat Jalan Rumah Sakit Condong Catur Yogyakarta

Rr. Erni Kusuma Putri, Endang Darmawan, Dyah Aryani Perwitasari

DOI: https://doi.org/10.23917/pharmacon.v16i2.8915

Abstract

Type 2 diabetes mellitus is a chronic disease that requires lifelong therapy and high service costs so that the use of antidiabetic drugs affects the patient's therapeutic costs. The purpose of this study was to determine the cost of outpatient type 2 diabetes mellitus therapy for National Health Insurance (JKN) participants in Condong Catur Hospital Yogyakarta. The research method used is observational. The parameters measured are calculating the average direct medical costs (drug costs, doctor's examination and consultation fees, laboratory costs, medical treatment costs), and comparison between the costs of oral drugs, insulin, oral and insulin. The results of normality tests with Shapiro-Wilk (microvascular, microvascular and macrovascular), Kolmogorrov-Smirnov (macrovascular) p<0.05 indicate that data are not normally distributed, the results of the Kruskal Wallis test of the three groups (microvascular, macrovascular, microvascular and microvascular) show that differences are not normally distributed significant (p = 0.001).The results showed that the microvascular group therapy costs Rp 3,164,733.58 per month, the macrovascular group Rp 9,984,566.85 per month, the microvascular and macrovascular groups Rp 11,260,372.39 per month. The cost of therapy is based on the microvascular group drug Rp. 408,567.78 per month, the macrovascular group Rp. 1,245,987.48 per month, the microvascular and macrovascular groups Rp. 1,786,270.68 per month so that statistically from the three complications groups show significant differences p = 0,001 (p <0,005). The difference in the difference between the total real costs and the total INA-CBG's rates, the microvascular group Rp -38,741.14 per patient, the macrovascular group Rp -10,914.03 per patient, while in the microvascular and macrovascular group Rp 3,272.90 per patient shows that from to three groups of complications were not significantly different p = 0.207 (p> 0.005). Statistically it can be concluded that the cost of therapy based on antidiabetic drugs in the three groups of complications shows a significant difference. There is no significant difference in the difference between the real costs in the three groups of complications

Keywords

Real Costs, Type 2 Diabetes Mellitus, Complications

Full Text:

PDF

References

Acharya, L.D., Rau, N.R., Udupa, N., Rajan, M.S., Vijayanarayana, K., 2016. Assessment of cost of illness for diabetic patients in South Indian tertiary care hospital. Journal of Pharmacy & Bioallied Sciences. 8 (4): 314–320

American Diabetes Association, 2017. Standards of Medical Care in Diabetes, Diabetes Care Journal, 60-80.

Andayani, T.M., 2013. Farmakoekonomi Prinsip Dan Metodologi. Bursa Ilmu, Yogyakarta

Baroroh, F., Solikah, W.Y., Urfiyya, Q. A., 2016, Analisis BiayaTerapi Diabetes Melitus Tipe 2 di Rumah Sakit PKU Muhammadyah Bantul Yogyakarta, Jurnal Farmasi Sains dan Praktis, 1 (2), 11-22.

Barr, E.L.M., Zimmet, P.Z., Welborn,T.A, Jolley., D, Magliano, D.J, 2014. Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab), Journal of American Heart Assosiation, 151-153

BPJS, 2014, INA-CBGs Membuat Biaya Kesehatan Lebih Efektif, Info BPJS Kesehatan, 8,34

Dinas Kesehatan Propinsi Yogyakarta. 2017, Profil Kesehatan Propinsi di Yogyakarta Tahun 2017, diakses 9 Oktober 2018, http://www.depkes.go.id/resources/download/profil/PROFIL_KES_PROVINSI_2017/14_DIY_2017.pdf

Kementerian Kesehtan Republik Indonesia, 2013, Buku Pegangan Sosialisasi Jaminan Kesehatan Nasional (JKN) dalam Sistem Jaminan Sosial Nasional, 9-10,16,27, Kementerian Kesehatan RI, Jakarta.

Kementerian Kesehatan RI, 2014, Peraturan Menteri Kesehatan Republik Indonesia Nomor 27 Tahun 2014 tentang Petunjuk Teknis Sistem Indonesia Case Base Groups (INA-CBGs), Kementerian Kesehatan RI, Jakarta

Kementerian Kesehatan Republik Indonesia, 2014. Peraturan Menteri Kesehatan Republik Indonesia Indonesia Nomor 28 Tahun 2014 Tentang Pedoman Pelaksanaan Program Jaminan Kesehatan Nasional. Kementerian Kesehatan Republik Indonesia

Kim, T.H., Chun, K.H., Kim., H.J., Han, S.J., Kim, D.J., Kwak, J., Kim, Y.S., Woo, J.T., Park, Y., Nam, M., Baik, S.H., Ahn, K.J., Lee, K.W., 2012. Direct Medical Cost for Patients with Type 2 Diabetes and Related Complications: A Prospective Cohort Study Based on the Korean National Diabetes Program, J. Korean Med. Sci. 27, 876-882. doi: 10.3346/jkms.2012.27.8.876

Lingvay, I., Legendre, J.L., Kaloyanova, P.F., 2009. Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes. American Diabetes Association. Diabetes Care 32:1789-1795, 200

Malhan, S., Oksuz, E., Babineaux, S.M., Ertekin, A., dan Palmer, J.P., 2014. Assessment of the Direct Medical Costs of Type 2 Diabetes Mellitus and its Complications in Turkey. Turkish Journal of Endocrinology and Metabolism, 18: 39-43.

PERKENI, 2015, Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015, PB. PERKENI, Jakarta.

Watetu, T.A., Beatrice, K.N., Arnold, O., Anselimo M., 2019. Characteristics of Type 2 Diabetes Patients and Their Association with the Metabolic Syndrome and Cardiovascular Risk Factors at Thika Level Five Hospital in Kenya. International Journal of Diabetes and Endocrinology. 4(2): 35-48

World Health Organization (WHO), 2016, Global Report on Diabetes, France: World Health Organization.

Wu, Y., Ding, Y., Tanaka, Y., Zhang, W., 2014, Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention, International Journal of Medical Sciences, 11 (11), 1185-1200.

Yosmar, R., Almasdy, D., Rahma, F., 2018. Survei Risiko Penyakit Diabetes Melitus Terhadap Masyarakat Kota Padang. Jurnal Sains Farmasi & Klinis. 134–141.

Zhuo, X., Zhang, P., Hoerger, T.J., 2013, Lifetime Direct Medical Cost of Treating Type 2 Diabetes and Diabetic Complications, American Journal of Preventive Medicine, 45 (3), 253-261

Article Metrics

Abstract view(s): 346 time(s)
PDF: 480 time(s)

Refbacks

  • There are currently no refbacks.